Maze Therapeutics MAZE
NASDAQ MAZE
$35.67 +0.22 (+0.62%)
As of: Nov 11, 2026 · 9:42 AM EST

Maze Therapeutics (MAZE) Non Operating Interest Expenses (2026)

Updated

Maze Therapeutics (MAZE) posted Non Operating Interest Expenses of $931,000 for Q2 2026, up 7.5% from the prior quarter.

Analysis

Maze Therapeutics (MAZE) Non Operating Interest Expenses (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 217.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -477.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 653.00 Mn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 269.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Maze Therapeutics 2.00 Bn 506.07 Mn - 975,000.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 975,000.00
Jun 30, 2026 931,000.00
Mar 31, 2026 866,000.00
API Access

Maze Therapeutics Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=MAZE&period=max&api_key=YOUR_API_KEY